Lirametostat clinical trials
Also written CPI-1205.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses lirametostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CPI-1205
- 3
Studies by the year they started
3 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Constellation Pharmaceuticals (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lirametostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate CancerCompletedPhase 1/2Constellation PharmaceuticalsNCT03480646Written as CPI-1205
- A Study Evaluating CPI-1205 in Patients With B-Cell LymphomasCompletedPhase 1Constellation PharmaceuticalsNCT02395601Written as CPI-1205
- ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid TumorsCompletedPhase 1Constellation PharmaceuticalsNCT03525795Written as CPI-1205
Codes
What other systems call lirametostat · ClinicalTrials.gg INT000698
- MeSH (NLM) C000619999(R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 455J2479FYLIRAMETOSTATConfirmed FDA, NLM
- NCI Thesaurus C121639LirametostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619999 | (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 455J2479FY | LIRAMETOSTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C121639 | Lirametostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.